Aumilto Silva, Medical Oncologist and Clinical Research at Hospital Santa Catarina Paulista, shared a post on X:
“Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane. This real-world analysis (n = 215), baseline tumors were profiled using the HER2DX genomic assay integrating a 27-gene panel (immune, proliferation, luminal differentiation, HER2 amplicon).
High ERBB2 mRNA score was associated with:
- rwPFS – 33.8 vs 12.5 months HR 0.50 (p < 0.001)
- rwOS – Not reached vs 37.1 months. HR 0.36 (p < 0.001)
- ORR- 84.4% vs 52.0% (p < 0.001).
Patients with High ERBB2 score, < 3 metastatic sites, achieved a median rwPFS of 51.7 months. HER2DX genomic profiling provides independent prognostic information in patients with advanced HER2-positive breast cancer receiving first-line trastuzumab, pertuzumab, and taxane. Integration of ERBB2 expression, with luminal differentiation and proliferation signatures, may improve risk stratification beyond clinical variables alone.”
Title: Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane
Authors: Marcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, Bartłomiej Pyciński, Jesús Soberino, Ewa Chmielik, Esther Sanfeliu, Maria Rey, Francisco Pardo, Angela Aguirre, Oleguer Castillo, Aleksandra Lesniak, Malgorzata Oczko-Wojciechowska, Esther, Carcelero, Barbara Adamo, Maria Vidal, Milana Bergamino, Julia Maues, Guillermo Villacampa, Laia Paré, Patricia Villagrasa, Eva Ciruelos, Aleix Prat, Michal Jarzab, Fara Brasó-Maristany
Read The Full Article
Other articles featuring HER2DX on OncoDaily.